A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

NCT00758043 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

540

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C

Interventions

DRUG: telaprevir
DRUG: ribavirin
BIOLOGICAL: peginterferon alfa-2a

Sponsor

Vertex Pharmaceuticals Incorporated

Collaborators

[object Object]